Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California
Dates
study started
completion around
Principal Investigator
by Elizabeth Brem, MD

Description

Summary

This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). These are subjects who are newly diagnosed subjects with AML who are ineligible for intensive induction chemotherapy, relapsed/refractory CLL or newly diagnosed CLL.

Official Title

A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Keywords

Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory, AML, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Lymphoid Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Venetoclax, Pitavastatin

Eligibility

Location

  • Chao Family Comprehensive Cancer Center, University of California, Irvine
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Elizabeth Brem, MD
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 25 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT04512105
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 6 people participating
Last Updated